BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25867070)

  • 1. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90.
    Zunino B; Rubio-Patiño C; Villa E; Meynet O; Proics E; Cornille A; Pommier S; Mondragón L; Chiche J; Bereder JM; Carles M; Ricci JE
    Oncogene; 2016 Jan; 35(2):261-8. PubMed ID: 25867070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia.
    Pelz JO; Vetterlein M; Grimmig T; Kerscher AG; Moll E; Lazariotou M; Matthes N; Faber M; Germer CT; Waaga-Gasser AM; Gasser M
    Ann Surg Oncol; 2013 Apr; 20(4):1105-13. PubMed ID: 23456378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression changes induced by HIPEC in a murine model of gastric cancer.
    Graziosi L; Mencarelli A; Renga B; Santorelli C; Cantarella F; Bugiantella W; Cavazzoni E; Donini A; Fiorucci S
    In Vivo; 2012; 26(1):39-45. PubMed ID: 22210714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
    Iversen LH; Rasmussen PC; Laurberg S
    Br J Surg; 2013 Jan; 100(2):285-92. PubMed ID: 23124619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
    Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
    BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.
    Pelz JO; Doerfer J; Hohenberger W; Meyer T
    BMC Cancer; 2005 May; 5():56. PubMed ID: 15924622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model.
    Klaver YL; Hendriks T; Lomme RM; Rutten HJ; Bleichrodt RP; de Hingh IH
    Br J Surg; 2010 Dec; 97(12):1874-80. PubMed ID: 20806291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
    Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
    J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.
    Klaver CE; Musters GD; Bemelman WA; Punt CJ; Verwaal VJ; Dijkgraaf MG; Aalbers AG; van der Bilt JD; Boerma D; Bremers AJ; Burger JW; Buskens CJ; Evers P; van Ginkel RJ; van Grevenstein WM; Hemmer PH; de Hingh IH; Lammers LA; van Leeuwen BL; Meijerink WJ; Nienhuijs SW; Pon J; Radema SA; van Ramshorst B; Snaebjornsson P; Tuynman JB; Te Velde EA; Wiezer MJ; de Wilt JH; Tanis PJ
    BMC Cancer; 2015 May; 15():428. PubMed ID: 26003804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis.
    Detroz B; Laurent S; Honoré P; Blaffart F; Limet R; Meurisse M
    Acta Chir Belg; 2004 Aug; 104(4):377-83. PubMed ID: 15469146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
    Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J
    J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Peritoneal carcinomatosis of colorectal cancer: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
    Königsrainer I; Beckert S; Brücher B; Zieker D; Königsrainer A
    Dtsch Med Wochenschr; 2011 Sep; 136(36):1811-4. PubMed ID: 21882140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
    Balaphas A; Belfontali V; Ris F; Lanitis A; Meier RP; Amram ML; Roth A; Huber O; Berney T; Morel P
    Rev Med Suisse; 2016 Jun; 12(523):1190-4. PubMed ID: 27487625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Riss S; Mohamed F; Dayal S; Cecil T; Stift A; Bachleitner-Hofmann T; Moran B
    Eur J Surg Oncol; 2013 Sep; 39(9):931-7. PubMed ID: 23810280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed].
    Pocard M; Boige V
    Bull Cancer; 2005 Feb; 92(2):151-4. PubMed ID: 15749644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.